Intellia Therapeutics, Inc.

NTLA · XNAS

CIK 1652130fmd_19AMT2RXJE4D6E1C2FN25YSBEWManufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard

Coverage: Jan 01, 2015 to Sep 30, 2026, 47 periods

Ratios computed from the standardized statements. Select a value to open its proof.